Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics.

Marlowe JL, Akopian V, Karmali P, Kornbrust D, Lockridge J, Semple S.

Nucleic Acid Ther. 2017 Aug;27(4):183-196. doi: 10.1089/nat.2017.0671. Epub 2017 Jun 13.

PMID:
28609186
2.

Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics.

Henry SP, Seguin R, Cavagnaro J, Berman C, Tepper J, Kornbrust D.

Nucleic Acid Ther. 2016 Aug;26(4):210-5. doi: 10.1089/nat.2015.0593. Epub 2016 Mar 16. Review.

PMID:
26981618
3.

Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics.

Cavagnaro J, Berman C, Kornbrust D, White T, Campion S, Henry S.

Nucleic Acid Ther. 2014 Oct;24(5):313-25. doi: 10.1089/nat.2014.0490. Epub 2014 Aug 19. Review.

PMID:
25137397
4.

Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection.

Solano EC, Kornbrust DJ, Beaudry A, Foy JW, Schneider DJ, Thompson JD.

Nucleic Acid Ther. 2014 Aug;24(4):258-66. doi: 10.1089/nat.2014.0489.

PMID:
25054518
5.

Recommendations for safety pharmacology evaluations of oligonucleotide-based therapeutics.

Berman CL, Cannon K, Cui Y, Kornbrust DJ, Lagrutta A, Sun SZ, Tepper J, Waldron G, Younis HS.

Nucleic Acid Ther. 2014 Aug;24(4):291-301. doi: 10.1089/nat.2013.0477. Epub 2014 Jun 19. Review.

PMID:
24946015
6.

Oligo safety working group exaggerated pharmacology subcommittee consensus document.

Kornbrust D, Cavagnaro J, Levin A, Foy J, Pavco P, Gamba-Vitalo C, Guimond A.

Nucleic Acid Ther. 2013 Feb;23(1):21-8. doi: 10.1089/nat.2012.0399. Epub 2013 Jan 4.

PMID:
23289535
7.

Assessing unintended hybridization-induced biological effects of oligonucleotides.

Lindow M, Vornlocher HP, Riley D, Kornbrust DJ, Burchard J, Whiteley LO, Kamens J, Thompson JD, Nochur S, Younis H, Bartz S, Parry J, Ferrari N, Henry SP, Levin AA.

Nat Biotechnol. 2012 Oct;30(10):920-3. doi: 10.1038/nbt.2376. No abstract available.

PMID:
23051805
8.

Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.

Thompson JD, Kornbrust DJ, Foy JW, Solano EC, Schneider DJ, Feinstein E, Molitoris BA, Erlich S.

Nucleic Acid Ther. 2012 Aug;22(4):255-64. doi: 10.1089/nat.2012.0371.

9.

The Oligonucleotide Safety Working Group (OSWG).

Schubert D, Levin AA, Kornbrust D, Berman CL, Cavagnaro J, Henry S, Seguin R, Ferrari N, Shrewsbury SB.

Nucleic Acid Ther. 2012 Aug;22(4):211-2. doi: 10.1089/nat.2012.0383. No abstract available.

PMID:
22913593
10.

First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL.

Mol Ther. 2010 Feb;18(2):442-6. doi: 10.1038/mt.2009.273. Epub 2009 Nov 24.

11.

Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes.

Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ.

Mol Vis. 2008 May 28;14:997-1005.

12.

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.

Heidel JD, Yu Z, Liu JY, Rele SM, Liang Y, Zeidan RK, Kornbrust DJ, Davis ME.

Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21. Epub 2007 Mar 22.

13.

Oligodeoxynucleotide studies in primates: antisense and immune stimulatory indications.

Farman CA, Kornbrust DJ.

Toxicol Pathol. 2003 Jan-Feb;31 Suppl:119-22. Review.

PMID:
12597439
14.

Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.

Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, Jagels MA, Kornbrust DJ, Levin AA.

Int Immunopharmacol. 2002 Nov;2(12):1657-66.

PMID:
12469940
15.

Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys.

Webb MS, Tortora N, Cremese M, Kozlowska H, Blaquiere M, Devine DV, Kornbrust DJ.

Antisense Nucleic Acid Drug Dev. 2001 Jun;11(3):155-63.

PMID:
11446591
16.

Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey.

Sandberg JA, Sproul CD, Blanchard KS, Bellon L, Sweedler D, Powell JA, Caputo FA, Kornbrust DJ, Parker VP, Parry TJ, Blatt LM.

Antisense Nucleic Acid Drug Dev. 2000 Jun;10(3):153-62.

PMID:
10905552
17.

Inhibition of coagulation by a phosphorothioate oligonucleotide.

Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ.

Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):503-10.

PMID:
9361909
18.

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.

Henry SP, Taylor J, Midgley L, Levin AA, Kornbrust DJ.

Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):473-81.

PMID:
9361906
19.

Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.

Leeds JM, Henry SP, Truong L, Zutshi A, Levin AA, Kornbrust D.

Drug Metab Dispos. 1997 Aug;25(8):921-6.

20.

Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.

Henry SP, Bolte H, Auletta C, Kornbrust DJ.

Toxicology. 1997 Jun 27;120(2):145-55.

PMID:
9184201
21.

Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.

Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ.

J Pharmacol Exp Ther. 1997 May;281(2):810-6.

22.

An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.

Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, Jacoby HI.

J Pharmacol Exp Ther. 1997 Feb;280(2):988-1000.

23.
24.
25.
26.

Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Kornbrust D, Manoharan M, Sasmor HM, Schleich T, Tivel KL, Griffey RH.

J Pharmacol Exp Ther. 1996 May;277(2):923-37.

PMID:
8627575
27.

Subchronic toxicity studies with the leukotriene D4 antagonist RG 12525.

Bonnefoi MS, Kelley MF, Wells RE, Sanders JE, Jayyosi Z, Beys E, Kornbrust DJ, Langloss JM.

Fundam Appl Toxicol. 1995 Nov;28(1):129-38.

PMID:
8566477
28.

Induction of peroxisomal enzymes by a tetrazole-substituted 2-quinolinylmethoxy leukotriene D4 antagonist.

Kelley M, Groth-Watson A, Knoble D, Kornbrust D.

Fundam Appl Toxicol. 1994 Aug;23(2):298-303.

PMID:
7982537
29.

Thiobenzamide-induced hepatotoxicity: effects of substituents and route of administration on the nature and extent of liver injury.

Grossman SJ, Patrick DH, Kornbrust D, Smith PF, Herold EG, DeLuca JG, Zacchei AG.

Toxicol Appl Pharmacol. 1991 Dec;111(3):388-408.

PMID:
1746022
30.

Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors.

Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, Bokelman DL.

Am J Med. 1989 Oct 16;87(4A):28S-38S. Review.

PMID:
2679082
31.
32.

Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.

Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, Alberts AW.

J Pharmacol Exp Ther. 1989 Feb;248(2):498-505.

PMID:
2918466
33.

Preclinical evaluation of lovastatin.

MacDonald JS, Gerson RJ, Kornbrust DJ, Kloss MW, Prahalada S, Berry PH, Alberts AW, Bokelman DL.

Am J Cardiol. 1988 Nov 11;62(15):16J-27J. Review.

PMID:
3055920
34.

Variations on the standard protocol design of the hepatocyte DNA repair assay.

Barfknecht TR, Naismith RW, Kornbrust DJ.

Cell Biol Toxicol. 1987 Jun;3(2):193-207.

PMID:
3507255
36.

Effects of 1,1-dichloro-2,2-bis[p-chlorophenyl]ethylene (DDE) on lactation in rats.

Kornbrust D, Gillis B, Collins B, Goehl T, Gupta B, Schwetz B.

J Toxicol Environ Health. 1986;17(1):23-36.

PMID:
3950997
40.

Effect of silica and volcanic ash on the content of lung alveolar and tissue phospholipids.

Kornbrust DJ, Hatch GE.

Environ Res. 1984 Oct;35(1):140-53.

PMID:
6092047
41.
42.

Glutathione depletion by methyl chloride and association with lipid peroxidation in mice and rats.

Kornbrust DJ, Bus JS.

Toxicol Appl Pharmacol. 1984 Mar 15;72(3):388-99.

PMID:
6710490
43.
44.

Comparison of rat and hamster hepatocyte primary culture/DNA repair assays.

Kornbrust DJ, Barfknecht TR.

Environ Mutagen. 1984;6(1):1-11.

PMID:
6692797
45.

The role of glutathione and cytochrome P-450 in the metabolism of methyl chloride.

Kornbrust DJ, Bus JS.

Toxicol Appl Pharmacol. 1983 Feb;67(2):246-56.

PMID:
6836579
46.

Metabolism of methyl chloride to formate in rats.

Kornbrust DJ, Bus JS.

Toxicol Appl Pharmacol. 1982 Aug;65(1):135-43. No abstract available.

PMID:
6815832
47.

Association of inhaled [14C]methyl chloride with macromolecules from various rat tissues.

Kornbrust DJ, Bus JS, Doerjer G, Swenberg JA.

Toxicol Appl Pharmacol. 1982 Aug;65(1):122-34. No abstract available.

PMID:
6183790
48.

Microsomal lipid peroxidation. II. Stimulation by carbon tetrachloride.

Kornbrust DJ, Mavis RD.

Mol Pharmacol. 1980 May;17(3):408-14. No abstract available.

PMID:
7393216
50.

Microsomal lipid peroxidation. I. Characterization of the role of iron and NADPH.

Kornbrust DJ, Mavis RD.

Mol Pharmacol. 1980 May;17(3):400-7. No abstract available.

PMID:
6771519

Supplemental Content

Loading ...
Support Center